September 7, 2023 03:03 PM EDT

Bipartisan House group calls on FDA to ensure OTC and prescription versions of a drug cannot be marketed simultaneously

Zachary Brennan

Senior Editor

Reps. Debbie Dingell (D-MI), Robert Latta (R-OH) and Dan Crenshaw (R-TX) sent a letter yesterday to Patrizia Cavazzoni, the head of FDA’s Center for Drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bipartisan House group calls on FDA to ensure OTC and prescription versions of a drug cannot be marketed simultaneously

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Bi­par­ti­san House group calls on FDA to en­sure OTC and pre­scrip­tion ver­sions of a drug can­not be mar­ket­ed si­mul­ta­ne­ous­ly

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Bipartisan House group calls on FDA to ensure OTC and prescription versions of a drug cannot be marketed simultaneously